Congress funds antibiotic-resistance research network to combat drug-resistant infections
S. 5237 — Stop Superbugs Act · Filed by Maggie Hassan (D-NH) · 1 cosponsor · Introduced Aug 4, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the National Institute of Allergy and Infectious Diseases (NIAID) to award a competitive grant to the Antibiotic Resistance Leadership Group to establish a clinical research network focused on antibiotic resistance. The network will support faster recruitment of trial participants, community outreach, pairing of diagnostic and drug innovations in trials, and development of patient-reported outcome measures. Congress authorizes whatever funding is needed.
Why we flagged it
The bill is a straightforward appropriations authorization for clinical research infrastructure addressing antibiotic resistance, a documented public-health priority. It contains no tax provisions, regulatory changes, or private carve-outs.
What the text implies
- The bill does not specify funding amount, leaving appropriations to future congressional action—actual research capacity depends on whether Congress later votes to fund it.
- The 'Antibiotic Resistance Leadership Group' is not defined in the bill text; its structure, governance, and composition are left to NIAID discretion, creating implementation flexibility but also potential for mission drift.
- Community outreach and patient-reported outcomes language may expand trial participation among underrepresented populations, potentially improving generalizability of antibiotic-resistance research but also creating new data-collection burdens on participants.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Antibiotic resistance is a documented public-health threat; this bill funds research infrastructure and clinical trials to develop new treatments and diagnostics. Citizens benefit from expanded research capacity, faster trial recruitment, and community-centered research design. No restrictions on citizen rights or protections are imposed.
Who stands to gain
- research institutions and universities (as grant recipients)
- clinical trial networks and research coordinators
- diagnostic and pharmaceutical companies (through pairing innovations in trials)
Named in the bill
National Institute of Allergy and Infectious Diseases (NIAID), Antibiotic Resistance Leadership Group, U.S. Department of Health and Human Services
Where it stands
1 cosponsor: 1 Republicans.
- Aug 4, 2026 — Introduced · Congress.gov: “Introduced in Senate”
- Aug 4, 2026 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (914 characters) on Aug 12, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“Congress funds antibiotic-resistance research network to combat drug-resistant infections” QuorumCivic. https://share.quorumcivic.app/bill/119/s5237 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.